<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937350</url>
  </required_header>
  <id_info>
    <org_study_id>42430</org_study_id>
    <secondary_id>R01DK099199</secondary_id>
    <nct_id>NCT02937350</nct_id>
  </id_info>
  <brief_title>Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to better understand vitamin D catabolism and how it is affected by
      CKD and race. Specifically, the study team will evaluate the metabolic clearance of
      25-hydroxyvitamin D3 in individuals with varying degrees of CKD and among participants who
      self-report race as Caucasian, African American or African. The long-term goal of this work
      is to enhance the clinical evaluation and treatment of impaired vitamin D metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic clearance of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Metabolic clearance is calculated as the administered dose of 25(OH)D3 divided by the area under the plasma concentration-time curve (AUC). AUC is calculated using the linear trapezoidal method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>AUC is calculated using the linear trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Terminal half-life is equal to ln2/k, where k is the slope of the terminal regression line estimated using ≥3 plasma concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Volume of distribution in the central compartment is calculated as dose/C0, where dose is the administered dose of 25(OH)D3 and C0 is the initial (estimated) concentration of drug in plasma.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolic formation clearance of D6-25(OH)D3 metabolites.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Metabolic formation clearance is calculated as the daughter metabolite plasma AUC divided by the AUC of D6-25(OH)D3 (metabolite/parent AUC ratio). AUC is calculated using the linear trapezoidal method.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the serum concentration of calcium</measure>
    <time_frame>7 days</time_frame>
    <description>Change in the serum concentration of calcium from baseline to 7 days after 25(OH)D3 administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the serum concentration of creatinine</measure>
    <time_frame>7 days</time_frame>
    <description>Change in the serum concentration of creatinine from baseline to 7 days after 25(OH)D3 administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the serum concentration of AST</measure>
    <time_frame>7 days</time_frame>
    <description>Change in the serum concentration of AST from baseline to 7 days after 25(OH)D3 administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the serum concentration of ALT</measure>
    <time_frame>7 days</time_frame>
    <description>Change in the serum concentration of ALT from baseline to 7 days after 25(OH)D3 administration</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Study Population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D6-25-hydroxyvitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D6-25-hydroxyvitamin D3</intervention_name>
    <description>Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3</description>
    <arm_group_label>Study Population</arm_group_label>
    <other_name>stable isotope deuterium-labeled 25(OH)D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Self-reported race Caucasian, African American, or African

          -  Serum total 25(OH)D 10-50 ng/mL

          -  Estimated GFR:

               -  60 mL/min/1.73m2 (N=40) 15-45 mL/min/1.73m2 (N=40) &lt;15 mL/min/1.73m2, treated
                  with hemodialysis (N=40)

        Exclusion Criteria:

          -  Primary hyperparathyroidism

          -  Gastric bypass

          -  Tuberculosis or sarcoidosis

          -  Current pregnancy

          -  Child-Pugh Class B or C cirrhosis (i.e. cirrhosis with ascites, hepatic
             encephalopathy, bilirubin &gt;=2 mg/dL, serum albumin &lt;=3.5 g/dL, or PT &gt;= 4 seconds)

          -  Use of vitamin D3, or vitamin D2 supplements exceeding a mean daily dose of 400 IU,
             within 3 months (wash-out allowed)

          -  Use of 1,25(OH)2D3 or an analogue, calcimimetics, or medications known to induce
             CYP24A1 within 4 weeks (wash-out allowed)

          -  Serum calcium &gt; 10.1 mg/dL

          -  Hemoglobin &lt; 10 g/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian de Boer, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Curtin</last_name>
    <phone>2062213938</phone>
    <email>LCurtin@Nephrology.washington.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashveena Dighe</last_name>
    <phone>2067444029</phone>
    <email>ashveena@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Curtin</last_name>
      <phone>206-221-3938</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ian deBoer</investigator_full_name>
    <investigator_title>Associate Professor, Medicine/Nephrology</investigator_title>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>vitamin d catabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

